Therapeutic efficacy of bovine ultra-long CDR H3 antibody against BVDV in challenged BALB/c mouse model.

Front Immunol · 2026 · PMC13095820 · PMID 42023221

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

As a result, viral loads in the BVDV + CDR H3 antibody group were significantly lower than those in the BVDV+PBS group at all time points ( P < 0.05), differences were highly significant on days 3, 5 and 7 ( P < 0.01) and remained significant on days 10 and 14 ( P < 0.05).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.